Britain and America have hammered out a key bilateral deal that will ensure no duties on UK medicine exports entering the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase spending on medicines through the NHS. This commitment ensures that import taxes on these key goods will remain at zero for a period of 36 months.
This deal is in response to recent warnings to dramatically increase tariffs on branded pharmaceutical imports, with figures floated reaching one hundred percent.
"This arrangement between the Britain reinforces the international landscape for new treatments and establishes much-needed balance to transatlantic pharmaceutical trade," an announcement noted.
Commercial Significance
Drugs constitute one of the UK's biggest goods shipped to the United States, which is easily the biggest buyer for large British pharmaceutical firms.
Statistics reveal that in the 12 months to the end of September, the UK exported pharmaceutical products worth over eleven billion pounds to the US. This value represented a significant portion of all goods exports in that period.
"This agreement safeguards work, increases capital expenditure and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary remarked.
Detailed UK Commitments
The agreement involves several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it deems new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to double overall health service expenditure on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage drug companies must refund to the NHS to stay within budget will be restricted at 15%. Last year, rebates topped twenty percent.
Recent Tensions
This agreement comes amid a long-running row between the drug companies and the UK government over medicine costs and approval rates.
The disagreement were exacerbated by arguments that US patients were charged a premium for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or scrapped, while substantial investments have been pledged toward projects in the United States.
A senior figure stated that the NHS must spend more on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its total funding over the past decade.
